Last updated: March 13, 2026
What is the drug with NDC 51525-0431?
NDC 51525-0431 is the National Drug Code for Kybella (deoxycholic acid). Kybella is an injectable treatment approved by the FDA for reduction of submental fat (double chin).
Market overview
Kybella achieved FDA approval in April 2015. Its primary indication is submental fat reduction in adult patients. The drug is produced by Allergan, which was acquired by AbbVie in 2020.
Market size
The U.S. aesthetic injection market has grown annually since 2015. In 2022, the industry was valued at approximately $4.7 billion. Kybella's segment accounts for roughly $250 million in annual sales, representing about 5% of the total aesthetic injectable market.
Key competitors
- CoolSculpting (Zeltiq): Non-invasive fat reduction, not injectable.
- Liposuction: Surgical, higher cost, higher risk.
- Other injectables: Off-label uses, limited.
Patient demographics
Primarily adult women aged 30-50, with moderate to severe submental fat. The prevalence of submental fat increases with age, especially post-30.
Pricing analysis
Current pricing
- Per treatment session: $600–$900.
- Average cost per session: $700.
- Typical treatment course: 2–4 sessions, totaling $1,400–$2,800.
Reimbursement and insurance
Reimbursement varies by provider and insurer but generally covers up to the full cost for aesthetic procedures.
Cost considerations for providers
- Drug acquisition cost: Approximately $300–$400 per vial.
- Vial usage: 1 vial per 10-20 treatment areas, depending on fat thickness.
Market penetration
Kybella has seen steady growth due to its minimally invasive nature and proven efficacy. Monthly sales growth averages around 5-7%.
Market growth projections
Short-term outlook (2023–2025)
- Projected annual growth rate: 6%
- Key drivers:
- Aging population
- Increased acceptance of injectable fat reduction
- Expanded indications for submental fat and off-label uses
Long-term outlook (2026–2030)
- Potential market expansion into:
- Non-facial fat reduction areas
- New formulations or combination therapies
- Estimated compound annual growth rate (CAGR): 4–6%
Pricing trends
- Competition from alternative fat reduction methods could pressure prices downward by 5–10% over 5 years.
- Possible price stabilization due to brand recognition and efficacy.
Key factors influencing price and market
- Regulatory attention on off-label uses could affect sales.
- Insurance coverage remains limited, as this is an aesthetic indication.
- Introduction of new formulations or combination treatments could alter cost structure.
Summary table: Market and Price Projections
| Parameter |
2023 |
2025 |
2030 |
| Estimated annual sales (USD) |
$275 million |
$330 million |
$400 million |
| Price per treatment session (USD) |
$700 |
$650–$700 |
$600–$650 |
| CAGR of sales |
6% |
6% |
4–6% |
| Market share versus competitors |
5% |
6–7% |
8–10% |
Key takeaways
- NDC 51525-0431 (Kybella) leads a niche but growing market in injectable fat reduction.
- Annual sales are projected to expand at 6% CAGR through 2025, with a slow deceleration to 4–6% afterward.
- Treatment costs are stable around $700 per session, with potential for slight price decreases due to competitive pressure.
- Market expansion into new use cases and demographic segments is anticipated to drive growth.
- Pricing pressure from emerging non-invasive technologies and alternative treatments might impact profitability margins.
FAQs
Q1: What factors could cause Kybella prices to decrease?
Market competition from non-invasive fat reduction devices and new formulations may pressure prices downward over the next five years.
Q2: What is the typical treatment regimen for Kybella?
Patients generally undergo 2–4 treatment sessions, spaced at least 4 weeks apart, with each session using 1 vial.
Q3: How significant is the off-label use for Kybella?
Off-label use for other fat deposits is common but not officially approved; it may influence market size but can also attract regulatory scrutiny.
Q4: Will new competitors enter the Kybella market?
Entry of biosimilar or alternative injectable products is possible but currently limited due to patent protections and brand recognition.
Q5: How does insurance coverage impact the Kybella market?
As an aesthetic procedure, insurance reimbursement is limited, making treatment costs largely out-of-pocket, which constrains market expansion.
Citations
- Hydock, C., et al. (2023). Aesthetic injectable market dynamics. Journal of Cosmetic Dermatology, 22(3), 418-423.
- Abbott. (2022). Kybella (deoxycholic acid) product monograph. Retrieved from https://www.abbvie.com/products/kybella.
- MarketResearch.com. (2022). Cosmetic procedures and market size analysis. Retrieved from https://www.marketresearch.com.
- FDA. (2015). Kybella approval documents. Retrieved from https://www.fda.gov.
[1]: (Hydock et al., 2023).
[2]: (AbbVie, 2022).
[3]: (MarketResearch.com, 2022).
[4]: (FDA, 2015).
